Vaccine Delivery Markets for Microneedle Devices
|出版商||Greystone Research Associates||商品編碼||428083|
Vaccines are recognized as one of the most significant healthcare developments in the last one hundred years. In spite of their role in improving quality-of-life and drastically reducing the level of morbidity and mortality from infectious diseases, the ability of healthcare and state institutions to maximize access to many millions of underserved people has still not been realized. This is a complex picture that is characterized by significant regional and socioeconomic factors. One major obstacle is cost, particularly for many underdeveloped countries. Microneedle technology, which has been successfully used to delivery therapeutic drugs, continues to be investigated as a vaccine delivery method. The relative simplicity and safety of microneedles makes them well-suited for use in mass immunization as well as for single patients. Numerous companies are currently involved in clinical development to identify the true potential of this technology.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
‘Of the handful of prophylactic vaccines that have received regulatory approval for administration via microneedle delivery devices, the leading technology to date is clearly syringe-mounted microneedles, featuring either a single microneedle or a small array of several microneedles. These devices can be considered the first generation of devices for vaccine administration. Patch and stamp type devices featuring larger arrays, while under investigation, will likely eventually play a role in niche markets '